about
Brain investigation and brain conceptualizationThe clinical use of structural MRI in Alzheimer diseaseSuspected non-Alzheimer disease pathophysiology--concept and controversyImaging markers for Alzheimer disease: which vs howThe Worldwide Alzheimer's Disease Neuroimaging Initiative: An updateWorldwide Alzheimer's disease neuroimaging initiativeDelphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonanceDetection of the presenilin 1 COOH-terminal fragment in the extracellular compartment: a release enhanced by apoptosisDistinct patterns of brain activity in young carriers of the APOE-epsilon4 alleleAlzheimer's disease.Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.Computer-assisted imaging to assess brain structure in healthy and diseased brains.Brain connectivity in neurodegenerative diseases--from phenotype to proteinopathy.Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques.Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.Atypical nucleus accumbens morphology in psychopathy: another limbic piece in the puzzle.Multi-center comparison of medial temporal atrophy in patients with Alzheimer's disease--data from the ICTUS study.Aging.Neuroimaging outcomes in clinical trials in Alzheimer's disease.Hypergraphia and brain damage.Consensus paper: combining transcranial stimulation with neuroimaging.Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study.Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism.Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy.Medial temporal atrophy in early and late-onset Alzheimer's disease.Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer's diseaseComparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.Functional network disruption in the degenerative dementias.Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study.Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degenerationDisease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity.Virtual imaging laboratories for marker discovery in neurodegenerative diseases.Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans.Magnetic resonance imaging in Alzheimer's disease: from diagnosis to monitoring treatment effect.Norms for imaging markers of brain reserve.Progression of Alzheimer disease in Europe: data from the European ICTUS study.H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice.
P50
Q24604341-D078081C-D0D9-43BC-99E7-54CDA67FEE6FQ24609648-95AC9B7A-FA95-4016-929D-6D1C4BE326A3Q26771270-452C4640-6443-43A2-8422-2C8265AAD1BEQ27001254-A9946213-6E53-4297-B7B2-A3E09A6F593FQ27007843-BC17A9C8-0953-4489-8372-227C7F9C7A5BQ27010338-E2F89071-843E-4409-9144-9C22F86E75C5Q27310296-E69879FE-AA9E-4E6E-A93A-FF32CE6D0AACQ28572591-22932AF4-2CAE-47A5-B183-F188F826A55CQ29622928-994CCAD8-1DE5-477C-A89E-FA390D33D61FQ30251865-09ECCF51-6A13-4319-BDA8-C9D6C321B001Q30458193-BDC70953-BFCD-4AB4-A174-89A5B0811D29Q30810182-EE541F7A-136D-4DD0-868B-F4BA5D06A6C4Q30857734-35FA25CA-6EC4-4A9D-8F07-B51234545A2DQ31060498-78568B8A-CFA6-45BB-A1EE-75595E205FE3Q31063014-3194F8D4-3322-4A2B-834A-08CF2EA93A8BQ33355280-A2D248DD-152E-4B8D-9E1A-1814FB6DFB3CQ33374508-6BAF8820-AF7B-4141-B17E-A94E6F4664A2Q33378546-AAB0DFBC-1FF0-489E-846F-B4624D4366E4Q33415121-48A52450-9432-44FC-B8CD-058AF07A6BF3Q33591246-17A45425-B182-472B-863B-6D22328FEECEQ33633495-C42BDB25-42D7-4561-AD4D-23DBA5D4ACF5Q33650931-E011A91A-F4D4-45F7-94E6-F00BA0197FE1Q33713621-6DD6661C-2F53-4CE2-B8F2-67D09E395F51Q33734770-FE0A8941-5C0C-4AB2-B2B7-CB4316B4E0DDQ33742027-BE357924-F953-40C7-B3B2-8796330C4C4BQ33758587-DE2F91B8-5BF4-456A-A1BC-542C232F9B42Q33927545-B79C121F-A73B-4E1E-96BF-A430500E8060Q33937187-710F685D-AE2A-4473-918C-8F05C188E3FBQ33967680-AA10F26C-CABC-4139-874F-0C3182EAB3F6Q33998656-F6D374F2-19C3-40BB-85DD-05C1BDAADB01Q34038343-8BC52811-F167-49B4-AAC4-8C6F4300553CQ34039972-1ED0751E-7826-4EA1-B174-993EFCEBC18FQ34141768-B1CCCA26-AF0A-4809-A664-621BB9EF5625Q34197402-75FFEB2E-CDC0-4916-A5A4-D6BA47B1091EQ34201112-7552708C-C88C-49EA-A237-8A3CD2E24F1BQ34239277-F4F37EF7-EAA9-4DD0-AAE3-F0EC415DAEFCQ34294709-97F54BB9-FD0A-431B-90D9-E8D5DD07BB9DQ34320212-838EA4A8-3291-4B37-9273-B4631E0B772EQ34325847-23487043-4B0D-48E3-B4F6-D7C98EDBCA4FQ34343830-4880B46B-74C9-4A60-A562-BF3281C848D8
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Giovanni B Frisoni
@nl
Giovanni B Frisoni
@sl
Giovanni B. Frisoni
@en
Giovanni B. Frisoni
@es
type
label
Giovanni B Frisoni
@nl
Giovanni B Frisoni
@sl
Giovanni B. Frisoni
@en
Giovanni B. Frisoni
@es
prefLabel
Giovanni B Frisoni
@nl
Giovanni B Frisoni
@sl
Giovanni B. Frisoni
@en
Giovanni B. Frisoni
@es
P108
P214
P244
P1053
K-1360-2016
P106
P1153
56214208300
P21
P214
P244
nb98085656
P2456
P31
P3829
P396
IT\ICCU\CFIV\133329
P496
0000-0002-6419-1753
P569
1961-01-01T00:00:00Z
P735
P7859
lccn-nb98085656